Immunotherapy

Lorus announces European patent to protect unique tumor suppressor

Published in Gene Therapy Weekly, July 1st, 2004

Lorus Therapeutics, Inc.'s, wholly owned subsidiary, GeneSense Technologies, Inc., has been allowed a patent by the European Patent Office for its discovery of a gene, which suppresses the growth of malignant tumors.

The patent, titled "Suppression of Malignancy Utilizing Ribonucleotide Reductase R1," protects an innovative approach to inhibiting tumor growth in mammals, including humans. Using a vector delivery system, a tool of gene therapy, the tumor suppressor gene sequence is delivered to cancer cells and the resulting expression of the gene inhibits tumor growth.

Preclinical studies demonstrated markedly suppressed tumor growth. The gene can...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-07-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry